Research Article
Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study
Table 2
Crude and adjusted hazard ratio of CVD with or without acarbose use.
| Risk factor | Developed CVD
| Did not develop CVD
| Crude | | Adjusted | | HR | 95% CI | | HR | 95% CI | | Low | Up | | Low | Up | |
| Never use of acarbose | 33203 | 502450 | Ref. | — | — | | Ref. | — | — | — | Ever use of acarbose | 5081 | 104058 | 0.66 | 0.641 | 0.680 | <0.001 | 0.99 | 0.958 | 1.019 | 0.443 | Cumulative duration of therapy (months) | | | | | | | | | | | 12 | 4216 | 69976 | 0.83 | 0.802 | 0.855 | <0.001 | 1.19 | 1.152 | 1.231 | <0.001 | 12–24 | 545 | 17345 | 0.42 | 0.387 | 0.459 | <0.001 | 0.70 | 0.643 | 0.762 | <0.001 | 24 | 320 | 16737 | 0.24 | 0.217 | 0.271 | <0.001 | 0.38 | 0.341 | 0.425 | <0.001 | Cumulative dose (mg) | | | | | | | | | | | 1–54,750 | 4373 | 75757 | 0.79 | 0.769 | 0.819 | <0.001 | 1.14 | 1.105 | 1.18 | <0.001 | 54,751–109,500 | 449 | 15273 | 0.39 | 0.357 | 0.43 | <0.001 | 0.64 | 0.583 | 0.704 | <0.001 | 109,500 | 259 | 13028 | 0.25 | 0.219 | 0.28 | <0.001 | 0.41 | 0.360 | 0.460 | <0.001 |
|
|
Adjusted age, gender, other diabetic medications, and CCI. CVD: cardiovascular disease.
|